Inhibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without affecting ATRA-induced differentiation

Cancer Research

Volumn 69, Issue 3, 2009, Pages 1027-1036

  Billottet, Clotilde ^a   Banerjee, Lalita ^b   Vanhaesebroeck, Bart ^a,c   Khwaja, Asim ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; DOXORUBICIN; ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1; PROTEIN P110 ALPHA; PROTEIN P110 BETA; PROTEIN P110 DELTA; PROTEIN P110 GAMMA; PROTEIN S6; RAPAMYCIN; RETINOIC ACID; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH PROCESSES; HUMANS; ISOENZYMES; LEUKEMIA, PROMYELOCYTIC, ACUTE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; SIROLIMUS; SUBSTRATE SPECIFICITY; TRETINOIN; UP-REGULATION;

EID: 59149096169     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2608     Document Type: Article

References (50)

1. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98:1312-20.
2. Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. Oncogene 2004;23:7164-77.
3. Jing Y, Wang L, Xia L, et al. Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 2001;97:264-9.
4. Gale RE, Hills R, Pizzey AR, et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005;106:3768-76.
5. Bowen DT, Frew ME, Hills R, et al. RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years. Blood 2005;106:2113-9.
6. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002;296:1655-7.
7. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci 1997;22:267-72.
8. Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110{β} isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110{γ}. Proc Natl Acad Sci U S A 2008;105:8292-7.
9. Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110δ, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 1997;94:4330-5.
10. Leopoldt D, Hanck T, Exner T, Maier U, Wetzker R, Nurnberg B. Ghγ stimulates phosphoinositide 3-kinase-γ by direct interaction with two domains of the catalytic p110 subunit. J Biol Chem 1998;273:7024-9.
11. Foukas LC, Claret M, Pearce WP, et al. Key role for the p110a phosphoinositide 3-kinase in growth and metabolic regulation. Nature 2006;441:366-70.
12. Vanhaesebroeck B, Ali K, Bilancio A, Geering B, Foukas LC. Signalling by PI3Kisoforms: insights from gene-targeted mice. Trends Biochem Sci 2005;30:194-204.
13. Ali K, Camps M, Pearce WP, et al. Isoform-specific functions of phosphoinositide 3-kinases: p110 γ but not p110 γ promotes optimal allergic responses in vivo. J Immunol 2008;180:2538-44.
14. Knight ZA, Gonzalez B, Feldman ME, et al. A pharmacological map of the PI3-Kfamily defines a role for p110β in insulin signaling. Cell 2006;125:733-47.
15. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol 2003;3:426-34.
16. Samuels Y, Diaz LA, Jr., Schmidt-Kittler O, et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 2005;7:561-73.
17. Kang S, Denley A, Vanhaesebroeck B, Vogt PK. Oncogenic transformation induced by the p110β, -γ, and -δ isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 2006;103:1289-94.
18. Parsons R. Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 2004;15:171-6.
19. Lee JW, Soung YH, Kim SY, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005;24:1477-80.
20. Muller CI, Miller CW, Hofmann WK, et al. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res 2007;31:27-32.
21. Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007;21:1921-30.
22. Tamburini J, Chapuis N, Bardet V, et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008;111:379-82.
23. Bhaskar PT, Hay N. The two TORCs and Akt. Dev Cell 2007;12:487-502.
24. Guertin DA, Stevens DM, Thoreen CC, et al. M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev Cell 2006;11:859-71.
25. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
26. Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006;6:729-34.
27. Marone R, Cmiljanovic V, Giese B, Wymann MP. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta 2008;1784:159-85.
28. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110{δ} isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005;106:1063-6.
29. Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p110δ isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006;25:6648-59.
30. Scholl S, Bondeva T, Liu Y, Clement JH, Hoffken K, Wetzker R. Additive effects of PI3-kinase and MAPK activities on NB4 cell granulocyte differentiation: potential role of phosphatidylinositol 3-kinase γ. J Cancer Res Clin Oncol 2008;134:861-72.
31. Lal L, Li Y, Smith J, et al. Activation of the p70 S6 kinase by all- trans-retinoic acid in acute promyelocytic leukemia cells. Blood 2005;105:1669-77.
32. Poh TW, Pervaiz S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res 2005;65:6264-74.
33. Jaswon MS, Khwaja A, Roberts PJ, Jones HM, Linch DC. The effects of rhGM-CSF on the neutrophil respiratory burst when studied in whole blood. Br J Haematol 1990;75:181-7.
34. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
35. Chomienne C, Ballerini P, Balitrand N, et al. All-trans retinoic acid in acute promyelocytic leukemias. II. In vitro studies: structure-function relationship. Blood 1990;76:1710-7.
36. Drach J, Lopez-Berestein G, McQueen T, Andreeff M, Mehta K. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all- trans-retinoic acid. Cancer Res 1993;53:2100-4.
37. Xia L, Wurmbach E, Waxman S, Jing Y. Upregulation of Bfl-1/A1 in leukemia cells undergoing differentiation by all-trans retinoic acid treatment attenuates chemotherapeutic agent-induced apoptosis. Leukemia 2006;20:1009-16.
38. Doepfner KT, Boller D, Arcaro A. Targeting receptor tyrosine kinase signaling in acute myeloid leukemia. Crit Rev Oncol Hematol 2007;63:215-30.
39. Bertagnolo V, Neri LM, Marchisio M, Mischiati C, Capitani S. Phosphoinositide 3-kinase activity is essential for all- trans-retinoic acid-induced granulocytic differentiation of HL-60 cells. Cancer Res 1999;59:542-6.
40. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125-37.
41. Sarbassov DD, Ali SM, Sengupta S, et al. M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
42. Zeng Z, Sarbassov dos D, Samudio IJ, et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 2007;109:3509-12.
43. Matkovic K, Brugnoli F, Bertagnolo V, Banfic H, Visnjic D. The role of the nuclear Akt activation and Akt inhibitors in all- trans-retinoic acid-differentiated HL-60 cells. Leukemia 2006;20:941-51.
44. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004;15:177-82.
45. Castaigne S, Chomienne C, Daniel MT, et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990;76:1704-9.
46. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008;111:3395-402.
47. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001;7:680-6.
48. Mathieu J, Giraudier S, Lanotte M, Besancon F. Retinoid-induced activation of NF-κB in APL cells is not essential for granulocytic differentiation, but prolongs the life span of mature cells. Oncogene 2005;24:7145-55.
49. Hayakawa M, Kaizawa H, Moritomo H, et al. Synthesis and biological evaluation of 4-morpholino-2-phenylquinazolines and related derivatives as novel PI3 kinase p110α inhibitors. Bioorg Med Chem 2006;14:6847-58.
50. Condliffe AM, Davidson K, Anderson KE, et al. Sequential activation of class IB, class IA. PI3Kis important for the primed respiratory burst of human but not murine neutrophils. Blood 2005;106:1432-40.